

INFORMATION DISCLOSURE STATEMENT

(37 CFR 1.56, 1.97, and 1.98)

SHEET 1 OF 1

ATTORNEY DOCKET
TLLK-028/01 US

APPLICATION NO.
09/903,442

APPLICANT(S)

Lawrence M. Kauvar, et al.

FILING DATE

February 27, 2002

GROUP

1619

U.S. PATENT DOCUMENTS

†EXR INITIAL	REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)

FOREIGN PATENT DOCUMENTS

†EXR INITIAL	* REF. #	COUNTRY	PATENT NUMBER	DATE (MO/YR)	APPLICANT	TRANSLATION/ NOTES
<i>lm</i>	1A	WO	00/44366	08/2000	Telik, Inc.	

OTHER DOCUMENTS

†EXR INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
<i>lm</i>	2A	Z. Pavelic et al., "Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir", Poster Abstract; 1 April 2003; obtained from http://www.dekker.com/servlet/product/DOI/101081LPR120017490/section/abstract_38
<i>lm</i>	3A	R.J.H. Stenekes et al., "Degradable dextran microspheres for the controlled release of liposomes", <i>Int. J. Pharmaceutics</i> , 214, 17-20 (2001)
<i>lm</i>	4A	D. Reimer et al., "Cyclosporin (CSA) release from microemulsion: effect of membrane apposition", CSPA 5 th Symposium on Pharmaceutical Sciences '02, <i>J. Pharm. Pharmaceut. Sci.</i> (www.ualberta.ca/~csps), 5(2), 39-122 (2002)

EXAMINER'S SIGNATURE

Kuhn

DATE CONSIDERED

12/04

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered.
Include copy of this form in next communication to applicant.

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).